2 months ago
TNGX
AnalystsCharles ZhuCharles Zhu's Stock Forecasts
AnalystsCharles Zhu
Sectors:
Industries:
Analyst Ranking
Top 24%
#1215 out of 5160 analysts
Average Return
+23.61%
Win Rate
44%8 out of 18
Risk vs Reward
Poor
Good
Charles Zhu's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Tango Therapeutics IncTNGX | +183.04% | $2.83 | $8.01 | 2024-11-06 - 2025-11-06 | Strong Buy |
Ideaya Biosciences IncIDYA | +162.81% | $17.21 | $45.23 | 2023-03-07 - 2024-03-07 | Strong Buy |
Ideaya Biosciences IncIDYA | +134.58% | $12.52 | $29.37 | 2022-09-12 - 2023-09-12 | Strong Buy |
Merus NvMRUS | +113.41% | $22.96 | $49.00 | 2023-08-07 - 2024-08-07 | Strong Buy |
Nuvalent IncNUVL | +79.33% | $46.01 | $82.51 | 2023-07-23 - 2024-07-23 | Strong Buy |
Charles Zhu Analyst Color
Get additional color on Charles Zhu's coverage of popular stocks
Charles Zhu's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tango Therapeutics IncTNGX | 4 | Strong Buy | $12.00 | +38.41% | Maintains | 2 months ago |
Merus NvMRUS | 4 | Hold | $97.00 | +0.08% | Downgrades | 3 months ago |
Crescent Biopharma IncCBIO | 1 | Buy | $22.00 | +78.14% | Initiates Coverage On | 6 months ago |
Macrogenics IncMGNX | 2 | Strong Buy | $12.00 | N/A | Upgrades | 2 years ago |
Nuvalent IncNUVL | 1 | Strong Buy | $56.00 | N/A | Initiates Coverage On | 2 years ago |
Protara Therapeutics IncTARA | 1 | Strong Buy | $22.00 | N/A | Assumes | 2 years ago |
Cogent Biosciences IncCOGT | 3 | Strong Buy | $26.00 | N/A | Reiterates | 3 years ago |
Ideaya Biosciences IncIDYA | 2 | Strong Buy | $32.00 | N/A | Reiterates | 3 years ago |
Point Biopharma Global IncPNT | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.